Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
Lyra Therapeutics Inc (NASDAQ: LYRA) closed the day trading at $0.17 down -4.07% from the previous closing price of $0.17. In other words, the price has decreased by -$4.07 from its previous closing price. On the day, 1.46 million shares were traded. LYRA stock price reached its highest trading level at $0.1779 during the session, while it also had its lowest trading level at $0.163.
Ratios:
For a better understanding of LYRA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.41 and its Current Ratio is at 3.41. In the meantime, Its Debt-to-Equity ratio is 2.97 whereas as Long-Term Debt/Eq ratio is at 2.61.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on May 07, 2024, Downgraded its rating to Hold and sets its target price to $0.50 from $10 previously.
On May 07, 2024, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $12 to $2.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LYRA now has a Market Capitalization of 10870299 and an Enterprise Value of 4673292. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.06 while its Price-to-Book (P/B) ratio in mrq is 0.93. Its current Enterprise Value per Revenue stands at 3.046 whereas that against EBITDA is -0.078.
Stock Price History:
The Beta on a monthly basis for LYRA is -0.08, which has changed by -0.9726821 over the last 52 weeks, in comparison to a change of 0.09589827 over the same period for the S&P500. Over the past 52 weeks, LYRA has reached a high of $6.79, while it has fallen to a 52-week low of $0.16. The 50-Day Moving Average of the stock is -14.66%, while the 200-Day Moving Average is calculated to be -32.75%.
Shares Statistics:
Over the past 3-months, LYRA traded about 1.25M shares per day on average, while over the past 10 days, LYRA traded about 1016980 shares per day. A total of 65.52M shares are outstanding, with a floating share count of 54.51M. Insiders hold about 16.73% of the company’s shares, while institutions hold 38.12% stake in the company. Shares short for LYRA as of 1740700800 were 1877045 with a Short Ratio of 1.50, compared to 1738281600 on 2138172. Therefore, it implies a Short% of Shares Outstanding of 1877045 and a Short% of Float of 3.58.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$1.0 and -$1.0 for the fiscal current year, implying an average EPS of -$1.0. EPS for the following year is -$0.73, with 1.0 analysts recommending between -$0.73 and -$0.73.
Revenue Estimates
2 analysts predict $240k in revenue for the current quarter. It ranges from a high estimate of $380k to a low estimate of $100k. As of the current estimate, Lyra Therapeutics Inc’s year-ago sales were $532kFor the next quarter, 2 analysts are estimating revenue of $242k. There is a high estimate of $384k for the next quarter, whereas the lowest estimate is $100k.
A total of 3 analysts have provided revenue estimates for LYRA’s current fiscal year. The highest revenue estimate was $1.54M, while the lowest revenue estimate was $398k, resulting in an average revenue estimate of $1.15M. In the same quarter a year ago, actual revenue was $1.53MBased on 3 analysts’ estimates, the company’s revenue will be $8.88M in the next fiscal year. The high estimate is $18.9M and the low estimate is $398k.